New peer-reviewed, full-text, free HCV articles

Posted on April 28, 2015

See below for a list of new peer-reviewed, full-text, free HCV articles, available free for a limited time, only in our American Journal of Medicine Hepatitis C Resource Center (

New peer-reviewed, full-text article in the section of our Resource Center focused toward Primary Care Providers 

Internal PubMed link provided for you to review the abstract only, please visit the American Journal of Medicine Hepatitis C Resource Center to access the free full-text article

Hepatitis C.

Webster DP, Klenerman P, Dusheiko GM.

Lancet. 2015 Mar 21;385(9973):1124-35. doi: 10.1016/S0140-6736(14)62401-6. Epub 2015 Feb 14. Review.

New peer-reviewed, full-text articles in the section of the Resource Center focused toward Hepatologists, Gastroenterologists & Infectious Disease Specialists

Internal PubMed links provided for you to review the abstracts only, please visit the American Journal of Medicine Hepatitis C Resource Center to access the free full-text articles

Molecular epidemiology of newly acquired hepatitis C infections in England 2008-2011: Genotype, phylogeny and mutation analysis.

May S, Ngui SL, Collins S, Lattimore S, Ramsay M, Tedder RS, Ijaz S.

J Clin Virol. 2015 Mar;64:6-11. doi: 10.1016/j.jcv.2014.12.014. Epub 2014 Dec 27.

Resistance to hepatitis C virus: potential genetic and immunological determinants.

Mina MM, Luciani F, Cameron B, Bull RA, Beard MR, Booth D, Lloyd AR.

Lancet Infect Dis. 2015 Apr;15(4):451-460. doi: 10.1016/S1473-3099(14)70965-X. Epub 2015 Feb 19. Review.

HCV RNA measurement in samples with diverse genotypes using versions 1 and 2 of the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV test.

Pyne MT, Mallory M, Hillyard DR.

J Clin Virol. 2015 Apr;65:54-7. doi: 10.1016/j.jcv.2015.02.002. Epub 2015 Feb 7.

A novel method for the measurement of hepatitis C virus infectious titres using the IncuCyte ZOOM and its application to antiviral screening.

Stewart H, Bartlett C, Ross-Thriepland D, Shaw J, Griffin S, Harris M.

J Virol Methods. 2015 Mar 20;218:59-65. doi: 10.1016/j.jviromet.2015.03.009. [Epub ahead of print].

Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.

Aspinall EJ, Hutchinson SJ, Janjua NZ, Grebely J, Yu A, Alavi M, Amin J, Goldberg DJ, Innes H, Law M, Walter SR, Krajden M, Dore GJ.

J Hepatol. 2015 Feb;62(2):269-77. doi: 10.1016/j.jhep.2014.09.001. Epub 2014 Sep 6. 

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, Tran A, Larrey DG, Ratziu V, Alric L, Hyland RH, Jiang D, Doehle B, Pang PS, Symonds WT, Subramanian GM, McHutchison JG, Marcellin P, Habersetzer F, Guyader D, Grangé JD, Loustaud-Ratti V, Serfaty L, Metivier S, Leroy V, Abergel A, Pol S.

Lancet Infect Dis. 2015 Apr;15(4):397-404. doi: 10.1016/S1473-3099(15)70050-2. Epub 2015 Mar 13.

Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: A retrospective clinical-pathological study.

K-Kutala B, Bedossa P, Guedj J, Asselah T, Martinot-Peignoux M, Duval X, Marcellin P.

Dig Liver Dis. 2015 Apr;47(4):296-302. doi: 10.1016/j.dld.2014.12.010. Epub 2014 Dec 25.

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.

Kohli A, Osinusi A, Sims Z, Nelson A, Meissner EG, Barrett LL, Bon D, Marti MM, Silk R, Kotb C, Gross C, Jolley TA, Sidharthan S, Petersen T, Townsend K, Egerson D, Kapoor R, Spurlin E, Sneller M, Proschan M, Herrmann E, Kwan R, Teferi G, Talwani R, Diaz G, Kleiner DE, Wood BJ, Chavez J, Abbott S, Symonds WT, Subramanian GM, Pang PS, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S.

Lancet. 2015 Mar 21;385(9973):1107-13. doi: 10.1016/S0140-6736(14)61228-9. Epub 2015 Jan 13.

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.

Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B.

Lancet. 2015 Mar 21;385(9973):1075-86. doi: 10.1016/S0140-6736(14)61795-5. Epub 2014 Nov 11. Erratum in: Lancet. 2015 Mar 21;385(9973):1074.

Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection.

Lawitz E, Sullivan G, Rodriguez-Torres M, Bennett M, Poordad F, Kapoor M, Badri P, Campbell A, Rodrigues L Jr, Hu Y, Pilot-Matias T, Vilchez RA.

J Infect. 2015 Feb;70(2):197-205. doi: 10.1016/j.jinf.2014.09.008. Epub 2014 Sep 22.

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.

Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, Massetto B, Gaggar A, Ni L, Svarovskaia E, Brainard D, Subramanian GM, McHutchison JG, Puoti M, Rockstroh JK; PHOTON-2 study team.

Lancet. 2015 Mar 21;385(9973):1098-106. doi: 10.1016/S0140-6736(14)62483-1. Epub 2015 Feb 4.

No Replies to "New peer-reviewed, full-text, free HCV articles"

    Join the discussion

    Some html is OK